Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of CNCT19 in Children and Adolescent(Pediatric) Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

NCT05667506 is registered in ClinicalTrials.gov with Juventas Cell Therapy Ltd. as lead sponsor.

NCT NCT05667506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05667506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of CNCT19 in Children and Adolescent(Pediatric) Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Lead sponsor
Juventas Cell Therapy Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 7, 2023
Completion date
May 30, 2027
Enrollment
47 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia